CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas

This trial is testing a new type of immunotherapy called CAR T-cell therapy, where a patient's own immune cells are specially engineered to attack a protein called CD30 found on certain lymphoma (blood cancer) cells. **You may be eligible if...** - You have CD30-positive Hodgkin lymphoma or Non-Hodgkin lymphoma that came back after a stem cell transplant - Your lymphoma did not respond to at least 2 chemotherapy regimens or anti-CD30 antibody treatment - You have newly diagnosed CD30-positive lymphoma and cannot complete standard chemotherapy - Your general health score (Karnofsky or Lansky) is above 60% - Your expected survival is more than 12 weeks - Your kidney and liver test results are within acceptable ranges **You may NOT be eligible if...** - You have active HIV infection or certain serious infections - You are pregnant or breastfeeding - You have severe heart, kidney, or liver problems Talk to your doctor to see if this trial is right for you.